Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @MEI_Pharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MEI_Pharma
-
More than 1.8 million people in the US alone will be diagnosed with cancer in 2020. This
#WorldCancerDay
Our team reflects on our mission to bring patients with cancer new and effective treatments that allow them to live better, longer loves. #CancerDay@uiccpic.twitter.com/Xv7YA7l4um
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The MEIP team volunteered at the
@SDFoodBank today. Thank you for all that you do for the community and your continual dedication since 1977!pic.twitter.com/WsQezRGy6X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This past year, we made progress in unlocking innovations in
#PI3K development, like intermittent dosing. In 2020, we look forward to further progressing our programs and exploring the potential our candidates hold alone and in combo. https://www.meipharma.com/2019ar/ pic.twitter.com/QFzCpaYHxB
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Senior VP for Clinical Development at
$MEIP, Richard Ghalie, makes a call to action for more patient-centric study designs in the below First Opinion article. He cites new and creative approaches to drug development, like novel uses of intermittent dosing. Check it out!https://twitter.com/statnews/status/1210213847778414595 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#TBT Back in Nov, we raised over $10,470 in support of#LightTheNight and@LLSusa to help bring new, innovative therapies to millions of people affected by#bloodcancers. Thanks again to all those who donated!pic.twitter.com/DLuyoFk2S9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
As the year comes to an end, we reflect on some of our highlights of 2019, including our PI3K investor & analyst event, CEO Dan Gold honored as a
#PharmaVOICE100 and COO David Urso as a finalist at#XconomyAwardsSanDiego, and being featured on#NasdaqSpotlight.pic.twitter.com/A27DKjfOfp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#JPM20 is just a few weeks away. We’re looking forward to meeting with other leaders and experts, and we’re excited to share what’s to come for$MEIP in 2020!pic.twitter.com/YWRHF1cFfw
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re evaluating ME-401 in
#FollicularLymphoma and#CLL /#SLL as a potent monotherapy and in combo with other powerful drug classes, including BTK inhibitors. We’re working to develop a PI3K-delta inhibitor that addresses the significant unmet needs in B-cell malignancies.pic.twitter.com/zJYdc1jbC3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PI3K-delta sits at the cross roads of a key B-cell malignancy signaling pathway. Check out our latest presentation to learn more about our distinct PI3K-delta inhibitor, ME-401, and the new generation of PI3K inhibition: https://investor.meipharma.com/corporate-presentation-10-19 …
$MEIPpic.twitter.com/Bl58PXqiJ9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re looking forward to attending
#ASH19 this weekend and hearing the latest#hematology research. Let’s connect if you’re in town!pic.twitter.com/SqANpk5U27
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We showed our support for
@LLSusa and those affected by blood cancers nationwide at the#LightTheNight walk last weekend. Inspired by all those who walked with us.pic.twitter.com/fWlNKYoI5l
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are almost at our fundraising goal! Help us support
@LLSusa and@LightTheNight to promote further progress in#BloodCancer research and bringing life-changing therapies to millions of people living with blood cancers.pic.twitter.com/iSeNN7G55X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Updated ME-401 data from our ongoing Ph. 1b trial was included in
@lymphomanews today! See below for the full article, “Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial.”https://bit.ly/2pTMBjwHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our team is on a mission to raise $5,000 in support of
@LLSusa and#LightTheNight walk next Saturday. If we reach our goal, we’ve pledged to match that amount for a total of $10,000!@LightTheNight https://pages.lls.org/ltn/sd/SanDiego19/MEIPharma …pic.twitter.com/qCoGEXVFI8Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to our guest speakers Dr. Lewis Cantley,
@DrMatasar and Dr. Nishitha Reddy for presenting at "A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies,” an$MEIP hosted event!pic.twitter.com/aQm1ESL0AM
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are live! Tune into our webcast now to listen to the
$MEIP team and guest speakers discuss the PI3K pathway, the B-cell malignancy treatment landscape and ME-401 clinical updates.#lymsm@DrMatasar https://investor.meipharma.com/events-webcasts pic.twitter.com/ERTBbhmSq4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced updated data from our ongoing Ph. 1b study of ME-401 in patients with relapsed or refractory follicular
#lymphoma and relapsed or refractory#CLL/#SLL. For more details about the data, check out our live webcast tomorrow morning: https://bit.ly/353kEpz#lymsmpic.twitter.com/aFJ3lKgIJm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don’t miss the
$MEIP investor & analyst event tomorrow, with guest speakers Dr. Lewis Cantley,@DrMatasar and Dr. Nishitha Reddy.pic.twitter.com/EMopJLAXYA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’ll be providing an in-depth overview of the PI3K pathway and a pipeline update at “A New Chapter in PI3Kδ Inhibition to Treat B-cell Malignancies,” an
$MEIP hosted investor & analyst event. Detailed info about the webcast and reception available here: https://bit.ly/2ldcxVH pic.twitter.com/BRlR20ncIL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CEO Dan Gold will be presenting at the
@WellsFargo Healthcare Conference in Boston on September 4, at 11:25 am ET. We hope to see you there! Also check out the live audio webcast of the event on the$MEIP website under Events & Presentations. https://prn.to/2L9mxJq pic.twitter.com/DzFKEv9niN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.